The approval of ArteraAI Prostate by the FDA as a software as a medical device (SaMD) means it can now be used at the point ...

Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market ...

Q2 2025 Earnings Call Transcript August 13, 2025 Hyperfine, Inc. reports earnings inline with expectations. Reported EPS is $ ...

Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to ...

Nature abhors a vacuum, rushing to fill it often chaotically. Policymakers, similarly, dislike a regulatory void. The urge to ...

The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera’s ArteraAI Prostate software. This ...

As artificial intelligence continues to revolutionize industries, its application in quality assurance is emerging as a ...

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

Abridge is looking for acquisitions after raising $700 million in 18 months. Here's what the red-hot health AI startup wants ...

Artificial intelligence is transforming healthcare — we must align government policies to support this progress. It will save ...

Hyperfine Inc. ( ($HYPR) ) has released its Q2 earnings. Here is a breakdown of the information Hyperfine Inc. presented to its investors.

Artificial intelligence is everywhere, from Google searches to health care. Dr. Yanjun Gao with CU Anschutz said it's not a question of if AI can be used, but how.